1. Development and characterization of influenza M2 ectodomain and/or hemagglutinin stalk-based dendritic cell-targeting vaccines.
- Author
-
Olukitibi, Titus Abiola, Ao, Zhujun, Azizi, Hiva, Mahmoudi, Mona, Coombs, Kevin, Kobasa, Darwyn, Kobinger, Gary, and Xiaojian Yao
- Subjects
INFLUENZA ,VESICULAR stomatitis ,FLU vaccine efficacy ,HEMAGGLUTININ ,H1N1 influenza ,EXTRACELLULAR matrix proteins ,AVIAN influenza - Abstract
A universal influenza vaccine is required for broad protection against influenza infection. Here, we revealed the efficacy of novel influenza vaccine candidates based on Ebola glycoprotein dendritic cell (DC)-targeting domain (E1M) fusion protein technology. The four copies of ectodomain matrix protein of influenza (tM2e) or M2e hemagglutinin stalk (HA stalk) peptides (HM2e) were fused with E1M to generate E1M-tM2e or E1M-HM2e, respectively. We demonstrated that E1M-HM2e- or E1M-tM2e-pseudotyped viral particles can efficiently target DC/macrophages in vitro and induced significantly high titers of anti-HA and/or anti-M2e antibodies in mice. Significantly, the recombinant vesicular stomatitis virus (rVSV)-E1M-tM2e and rVSV-E1MHM2e vaccines mediated rapid and potent induction of M2 or/and HA antibodies in mice sera and mucosa. Importantly, vaccination of rVSV-E1MtM2e or rVSV-E1M-HM2e protected mice from influenza H1N1 and H3N2 challenges. Taken together, our study suggests that rVSV-E1M-tM2e and rVSV-E1M-HM2e are promising candidates that may lead to the development of a universal vaccine against different influenza strains. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF